Cargill has made a $25 million anchor investment in BioGaia, a leading probiotics manufacturing.
Cargill (Minneapolis, MN) has made a $25 million anchor investment in BioGaia (Stockholm, Sweden), a leading probiotics manufacturing, securing an initial minority stake in the firm, and unlocking multiple opportunities for partnership and collaboration in digestive and immune health for both animal and human applications. The investment demonstrates Cargill’s continued commitment to expanding microbiome research and product development of digestive health products. For example, Cargill recently invested in a venture capital fund to support microbiome research and development.
“With our investment in BioGaia we believe that together, we can accelerate the growth and expansion of current health solutions available to consumers and build upon our combined leadership to tackle a number of health conditions addressable through the microbiome,” said Chuck Warta, president of Cargill Health Technologies. “Ultimately, our goal is to help animals and humans live more healthy days. We’re excited about how this investment will help to build our Cargill Health Technologies business, and we look forward to continued growth in this space.”
“It is with great pleasure that we welcome Cargill among our major shareholders,” said Peter Rothschild, CEO of BioGaia. “Cargill is a global leader in food and agriculture with vast experience in ingredients, fermentation and manufacturing both in the animal and human nutrition and health industries. We are excited by the beginning of this strategic partnership and have initiated a number of collaborations with them that will materialize during the coming years.”